PURPOSE: To develop a rapidly dissolving porous particle formulation of paclitaxel without Cremophor EL that is appropriate for quick intravenous administration. METHODS: A rapidly dissolving porous particle formulation of paclitaxel (AI-850) was created using spray drying. AI-850 was compared to Taxol following intravenous administration in a rat pharmacokinetic study, a rat tissue distribution study, and a human xenograft mammary tumor (MDA-MB-435) model in nude mice. RESULTS: The volume of distribution and clearance for paclitaxel following intravenous bolus administration of AI-850 were 7-fold and 4-fold greater, respectively, than following intravenous bolus administration of Taxol. There were no significant differences between AI-850 and Taxol in tissue concentrations and tissue area under the curve (AUC) for the tissues examined. Nude mice implanted with mammary tumors showed improved tolerance of AI-850, enabling higher administrable does of paclitaxel, which resulted in improved efficacy as compared to Taxol administered at its maximum tolerated dose (MTD). CONCLUSIONS: The pharmacokinetic data indicate that paclitaxel in AI-850 has more rapid partitioning from the bloodstream into the tissue compartments than paclitaxel in Taxol. AI-850, administered as an intravenous injection, has been shown to have improved tolerance in rats and mice and improved efficacy in a tumor model in mice when compared to Taxol.
PURPOSE: To develop a rapidly dissolving porous particle formulation of paclitaxel without Cremophor EL that is appropriate for quick intravenous administration. METHODS: A rapidly dissolving porous particle formulation of paclitaxel (AI-850) was created using spray drying. AI-850 was compared to Taxol following intravenous administration in a rat pharmacokinetic study, a rat tissue distribution study, and a human xenograft mammary tumor (MDA-MB-435) model in nude mice. RESULTS: The volume of distribution and clearance for paclitaxel following intravenous bolus administration of AI-850 were 7-fold and 4-fold greater, respectively, than following intravenous bolus administration of Taxol. There were no significant differences between AI-850 and Taxol in tissue concentrations and tissue area under the curve (AUC) for the tissues examined. Nude mice implanted with mammary tumors showed improved tolerance of AI-850, enabling higher administrable does of paclitaxel, which resulted in improved efficacy as compared to Taxol administered at its maximum tolerated dose (MTD). CONCLUSIONS: The pharmacokinetic data indicate that paclitaxel in AI-850 has more rapid partitioning from the bloodstream into the tissue compartments than paclitaxel in Taxol. AI-850, administered as an intravenous injection, has been shown to have improved tolerance in rats and mice and improved efficacy in a tumor model in mice when compared to Taxol.
Authors: Nuhad K Ibrahim; Neil Desai; Sewa Legha; Patrick Soon-Shiong; Richard L Theriault; Edgardo Rivera; Bita Esmaeli; Sigrid E Ring; Agop Bedikian; Gabriel N Hortobagyi; Julie A Ellerhorst Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531
Authors: W R Perkins; I Ahmad; X Li; D J Hirsh; G R Masters; C J Fecko; J Lee; S Ali; J Nguyen; J Schupsky; C Herbert; A S Janoff; E Mayhew Journal: Int J Pharm Date: 2000-04-25 Impact factor: 5.875
Authors: L van Zuylen; M O Karlsson; J Verweij; E Brouwer; P de Bruijn; K Nooter; G Stoter; A Sparreboom Journal: Cancer Chemother Pharmacol Date: 2001-04 Impact factor: 3.333
Authors: Sebastian Strieth; Martin E Eichhorn; Birgitta Sauer; Brita Schulze; Michael Teifel; Uwe Michaelis; Marc Dellian Journal: Int J Cancer Date: 2004-05-20 Impact factor: 7.396
Authors: Alain C Mita; Anthony J Olszanski; Richard C Walovitch; Raymond P Perez; Kathleen MacKay; David P Tuck; Cecilia Simmons; Susan Hammond; Monica M Mita; Muralidhar Beeram; Anne J Stone; Eric K Rowinsky; Lionel D Lewis Journal: Clin Cancer Res Date: 2007-06-01 Impact factor: 12.531
Authors: Priya Srinivasan; Jining Zhang; Amy Martin; Kristin Kelley; Janet M McNicholl; Robert W Buckheit; James M Smith; Anthony S Ham Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191
Authors: M Laird Forrest; Jaime A Yáñez; Connie M Remsberg; Yusuke Ohgami; Glen S Kwon; Neal M Davies Journal: Pharm Res Date: 2007-10-03 Impact factor: 4.200
Authors: B Zavan; V Vindigni; K Vezzù; G Zorzato; C Luni; G Abatangelo; N Elvassore; R Cortivo Journal: J Mater Sci Mater Med Date: 2008-08-30 Impact factor: 3.896